Evidence map›Paper›PMID 38130372›Full record

ArticleMolecular therapy. Nucleic acids2024

miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44.

Shang-Gin Wu, Tzu-Hua Chang, Meng-Feng Tsai, Yi-Nan Liu, Yen-Lin Huang, Chia-Lang Hsu, Han-Nian Jheng, Jin-Yuan Shih

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib forJournal for immunotherapy of cancer · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shang-Gin WuDepartment of Internal Medicine, National Taiwan University Cancer Center, National Taiwan University, Taipei 10672, Taiwan.
Tzu-Hua ChangDepartment of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei 10002, Taiwan.
Meng-Feng TsaiDepartment of Biomedical Sciences, Da-Yeh University, Changhua 51591, Taiwan.
Yi-Nan LiuDepartment of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei 10002, Taiwan.
Yen-Lin HuangDepartment of Pathology, National Taiwan University Cancer Center, National Taiwan University, Taipei 10672, Taiwan.
Chia-Lang HsuDepartment of Medical Research, National Taiwan University Hospital, National Taiwan University, Taipei 10002, Taiwan.
Han-Nian JhengDepartment of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei 10002, Taiwan.
Jin-Yuan ShihDepartment of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei 10002, Taiwan.
National Taiwan University Hospital · TWNational Taiwan University · TWDayeh University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osimertinib is an effective treatment option for patients with advanced non-small cell lung cancer (NSCLC) with

Indexed as

CD44EGFREMTepidermal growth factor receptorepithelial-to-mesenchymal transitionmiR-204MT: Noncoding RNAsosimertinib resistancestemnessTKItyrosine kinase inhibitor

Identifiers

PMID38130372
PMCPMC10733107
OpenAlexW4389346441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.